{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:59:48Z","timestamp":1785560388831,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-026-05702-y","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:47:57Z","timestamp":1785559677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Standardizing serial prostate MRI in active surveillance: a practical review of PRECISE scoring"],"prefix":"10.1007","author":[{"given":"Negar","family":"Firoozeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungwoo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdair F.","family":"Muglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Purysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Schieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-7632","authenticated-orcid":false,"given":"Antonio C.","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"5702_CR1","doi-asserted-by":"publisher","unstructured":"Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US. JAMA Netw Open. 2023;6(3):e231439. Epub 2023\/03\/03. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.1439. PubMed PMID: 36862409; PubMed Central PMCID: PMCPMC9982696 from Astellas, AstraZeneca, Pfizer, Bayer, Merck, Dendreon, Janssen, Foundation Medicine, Veracyte, Exact Sciences, Verana Health, and ConcertAI outside the submitted work. Dr Gaylis reported receiving personal fees from Janssen Pharmaceuticals outside the submitted work. No other disclosures were reported.","DOI":"10.1001\/jamanetworkopen.2023.1439"},{"issue":"5","key":"5702_CR2","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.juro.2012.07.024","volume":"188","author":"HA Vargas","year":"2012","unstructured":"Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, Moskowitz CS, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol. 2012;188(5):1732\u20138. Epub 2012\/09\/29. https:\/\/doi.org\/10.1016\/j.juro.2012.07.024. PubMed PMID: 23017866; PubMed Central PMCID: PMCPMC5617124.","journal-title":"J Urol"},{"issue":"6","key":"5702_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","volume":"203","author":"S Carlsson","year":"2020","unstructured":"Carlsson S, Benfante N, Alvim R, Sjoberg DD, Vickers A, Reuter VE, et al. Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. J Urol. 2020;203(6):1122\u20137. Epub 2019\/12\/24. https:\/\/doi.org\/10.1097\/JU.0000000000000713. PubMed PMID: 31868556; PubMed Central PMCID: PMCPMC7480884.","journal-title":"J Urol"},{"issue":"4","key":"5702_CR4","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00330-024-10866-6","volume":"35","author":"RA Campbell","year":"2025","unstructured":"Campbell RA, Wood A, Schwen Z, Ward R, Weight C, Purysko AS. MRI and active surveillance: thoughts from across the pond. Eur Radiol. 2025;35(4):2157\u201369. Epub 2024\/09\/13. https:\/\/doi.org\/10.1007\/s00330-024-10866-6. PubMed PMID: 39266769; PubMed Central PMCID: PMCPMC11913918.","journal-title":"Eur Radiol"},{"issue":"4","key":"5702_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","volume":"71","author":"CM Moore","year":"2017","unstructured":"Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, et al. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. Eur Urol. 2017;71(4):648\u201355. Epub 2016\/06\/29. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.011. PubMed PMID: 27349615.","journal-title":"Eur Urol"},{"issue":"30","key":"5702_CR6","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","volume":"33","author":"JJ Tosoian","year":"2015","unstructured":"Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol. 2015;33(30):3379\u201385. Epub 2015\/09\/02. https:\/\/doi.org\/10.1200\/JCO.2015.62.5764. PubMed PMID: 26324359; PubMed Central PMCID: PMCPMC4863946.","journal-title":"J Clin Oncol"},{"issue":"10","key":"5702_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382(10):917\u201328. Epub 2020\/03\/05. https:\/\/doi.org\/10.1056\/NEJMoa1910038. PubMed PMID: 32130814; PubMed Central PMCID: PMCPMC7323919.","journal-title":"N Engl J Med"},{"key":"5702_CR8","doi-asserted-by":"publisher","unstructured":"Elwenspoek MMC, Sheppard AL, McInnes MDF, Merriel SWD, Rowe EWJ, Bryant RJ, et al. Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(8):e198427. Epub 2019\/08\/08. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.8427. PubMed PMID: 31390032; PubMed Central PMCID: PMCPMC6686781 UK Clinician Scientist Fellowship during the conduct of the study and grants from UCare Grant outside the submitted work. No other disclosures were reported.","DOI":"10.1001\/jamanetworkopen.2019.8427"},{"issue":"3","key":"5702_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bju.15100","volume":"127","author":"DD Shapiro","year":"2021","unstructured":"Shapiro DD, Gregg JR, Lim AH, Nogueras-Gonzalez GM, Choi H, Kang HC, et al. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int. 2021;127(3):340\u20138. Epub 2020\/05\/02. https:\/\/doi.org\/10.1111\/bju.15100. PubMed PMID: 32357283; PubMed Central PMCID: PMCPMC9798524.","journal-title":"BJU Int"},{"key":"5702_CR10","doi-asserted-by":"publisher","unstructured":"Giganti F, Leni R, Wagaskar V, Gandaglia G, Barrett T, Panebianco V, et al. Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance. Eur Radiol. 2026. Epub 2026\/05\/04. https:\/\/doi.org\/10.1007\/s00330-026-12570-z. PubMed PMID: 42080884.","DOI":"10.1007\/s00330-026-12570-z"},{"issue":"4","key":"5702_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bju.15623","volume":"129","author":"S Luzzago","year":"2022","unstructured":"Luzzago S, Piccinelli ML, Mistretta FA, Bianchi R, Cozzi G, Di Trapani E, et al. Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU Int. 2022;129(4):524\u201333. Epub 2021\/10\/24. https:\/\/doi.org\/10.1111\/bju.15623. PubMed PMID: 34687137.","journal-title":"BJU Int"},{"issue":"1","key":"5702_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamasurg.2024.4811","volume":"160","author":"T Li","year":"2025","unstructured":"Li T, Nalavenkata S, Fainberg J. Imaging in Diagnosis and Active Surveillance for Prostate Cancer: A Review. JAMA Surg. 2025;160(1):93\u20139. Epub 2024\/11\/13. https:\/\/doi.org\/10.1001\/jamasurg.2024.4811. PubMed PMID: 39535781.","journal-title":"JAMA Surg"},{"issue":"2","key":"5702_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79(2):263\u201382. Epub 2020\/10\/12. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046. PubMed PMID: 33039206.","journal-title":"Eur Urol"},{"issue":"6","key":"5702_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2019.09","volume":"76","author":"TBL Lam","year":"2019","unstructured":"Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019;76(6):790\u2013813. Epub 2019\/10\/08. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.020. PubMed PMID: 31587989.","journal-title":"Eur Urol"},{"issue":"2","key":"5702_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243\u201362. Epub 2020\/11\/12. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042. PubMed PMID: 33172724.","journal-title":"Eur Urol"},{"issue":"4","key":"5702_CR16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA\/ASTRO\/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 2018;199(4):990\u20137. Epub 2018\/01\/15. https:\/\/doi.org\/10.1016\/j.juro.2018.01.002. PubMed PMID: 29331546.","journal-title":"J Urol"},{"issue":"3","key":"5702_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA\/ASTRO\/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018;199(3):683\u201390. Epub 2017\/12\/06. https:\/\/doi.org\/10.1016\/j.juro.2017.11.095. PubMed PMID: 29203269.","journal-title":"J Urol"},{"issue":"12","key":"5702_CR18","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.6004\/jnccn.2022.0063","volume":"20","author":"EM Schaeffer","year":"2022","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines(R) Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022;20(12):1288\u201398. Epub 2022\/12\/13. https:\/\/doi.org\/10.6004\/jnccn.2022.0063. PubMed PMID: 36509074.","journal-title":"J Natl Compr Canc Netw"},{"key":"5702_CR19","doi-asserted-by":"publisher","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340\u201351. Epub 2019\/03\/23. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033. PubMed PMID: 30898406.","DOI":"10.1016\/j.eururo.2019.02.033"},{"issue":"5","key":"5702_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","volume":"80","author":"P Rajwa","year":"2021","unstructured":"Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, et al. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. Eur Urol. 2021;80(5):549\u201363. Epub 2021\/05\/23. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.001. PubMed PMID: 34020828.","journal-title":"Eur Urol"},{"issue":"4","key":"5702_CR21","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s00330-019-06557-2","volume":"30","author":"F Giganti","year":"2020","unstructured":"Giganti F, Pecoraro M, Stavrinides V, Stabile A, Cipollari S, Sciarra A, et al. Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. Eur Radiol. 2020;30(4):2082\u201390. Epub 2019\/12\/18. https:\/\/doi.org\/10.1007\/s00330-019-06557-2. PubMed PMID: 31844959; PubMed Central PMCID: PMCPMC7062656.","journal-title":"Eur Radiol"},{"issue":"3","key":"5702_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","volume":"86","author":"C Englman","year":"2024","unstructured":"Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V, et al. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. Eur Urol. 2024;86(3):240\u201355. Epub 2024\/04\/01. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.014. PubMed PMID: 38556436.","journal-title":"Eur Urol"},{"issue":"5","key":"5702_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2214\/AJR.23.29518","volume":"221","author":"N Sanmugalingam","year":"2023","unstructured":"Sanmugalingam N, Sushentsev N, Lee KL, Caglic I, Englman C, Moore CM, et al. The PRECISE Recommendations for Prostate MRI in Patients on Active Surveillance for Prostate Cancer: A Critical Review. AJR Am J Roentgenol. 2023;221(5):649\u201360. Epub 2023\/06\/21. https:\/\/doi.org\/10.2214\/AJR.23.29518. PubMed PMID: 37341180.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"5702_CR24","doi-asserted-by":"publisher","first-page":"e242164","DOI":"10.1148\/radiol.242164","volume":"318","author":"F Giganti","year":"2026","unstructured":"Giganti F, Allen C, Dickinson L, Punwani S, Moore CM, Kirkham A. MRI for Active Surveillance in Prostate Cancer: How I Do It. Radiology. 2026;318(3):e242164. Epub 2026\/03\/03. https:\/\/doi.org\/10.1148\/radiol.242164. PubMed PMID: 41773966.","journal-title":"Radiology"},{"key":"5702_CR25","doi-asserted-by":"publisher","unstructured":"Klotz L, Loblaw A, Zhang L, Mamedov A, Vesprini D. Prognostic value of MR visibility\/invisibility in men on Active Surveillance. Prostate Cancer Prostatic Dis. 2025;28(4):879\u2009\u2013\u200986. Epub 2025\/01\/18. https:\/\/doi.org\/10.1038\/s41391-024-00932-x. PubMed PMID: 39824930.","DOI":"10.1038\/s41391-024-00932-x"},{"issue":"3","key":"5702_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","volume":"78","author":"V Stavrinides","year":"2020","unstructured":"Stavrinides V, Giganti F, Trock B, Punwani S, Allen C, Kirkham A, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol. 2020;78(3):443\u201351. Epub 2020\/05\/04. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.035. PubMed PMID: 32360049; PubMed Central PMCID: PMCPMC7443696.","journal-title":"Eur Urol"},{"issue":"3","key":"5702_CR27","doi-asserted-by":"publisher","first-page":"e244-e52","DOI":"10.1016\/j.clgc.2022.01.015","volume":"20","author":"K Saout","year":"2022","unstructured":"Saout K, Zambon A, Nguyen TA, Lucas C, Payrard-Starck C, Segalen T, et al. Impact of Multiparametric MRI and PSA Density on the Initial Indication or the Maintaining in Active Surveillance During Follow-Up in low-Risk Prostate Cancer. Clin Genitourin Cancer. 2022;20(3):e244-e52. Epub 2022\/02\/27. https:\/\/doi.org\/10.1016\/j.clgc.2022.01.015. PubMed PMID: 35216924.","journal-title":"Clin Genitourin Cancer"},{"key":"5702_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.urology.2021.05.035","volume":"155","author":"BH Press","year":"2021","unstructured":"Press BH, Khajir G, Ghabili K, Leung C, Fan RE, Wang NN, et al. Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology. 2021;155:96\u2013100. Epub 2021\/06\/05. https:\/\/doi.org\/10.1016\/j.urology.2021.05.035. PubMed PMID: 34087311.","journal-title":"Urology"},{"issue":"4","key":"5702_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.eururo.2020.06.030","volume":"78","author":"CE Chu","year":"2020","unstructured":"Chu CE, Lonergan PE, Washington SL, Cowan JE, Shinohara K, Westphalen AC, et al. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. Eur Urol. 2020;78(4):515\u20137. Epub 2020\/07\/08. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.030. PubMed PMID: 32631744.","journal-title":"Eur Urol"},{"issue":"16 suppl","key":"5702_CR30","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1200\/JCO.2026.44.16_suppl.5125","volume":"44","author":"M Bigarella","year":"2026","unstructured":"Bigarella M, Lawrence E, Wiedmer A, Cava JA, Lee C, Eickhoff JC, et al. Addition of 18F-DCFPyL PSMA PET to MRI to avoid unnecessary biopsy in men on active surveillance: Final results from a phase II diagnostic trial (PROMPT). J Clin Oncol. 2026;44(16 suppl):5125.","journal-title":"J Clin Oncol"},{"key":"5702_CR31","doi-asserted-by":"publisher","unstructured":"Abreu-Gomez J, Eberhardt SC, Chapin BF, Fennessy FM, Surasi DS, Weg ES, et al. MRI for Prostate Cancer Local Staging: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2026:1\u201313. Epub 2025\/12\/10. https:\/\/doi.org\/10.2214\/AJR.25.33846. PubMed PMID: 41370657.","DOI":"10.2214\/AJR.25.33846"},{"issue":"3","key":"5702_CR32","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1007\/s00330-020-07256-z","volume":"31","author":"F Giganti","year":"2021","unstructured":"Giganti F, Stabile A, Stavrinides V, Osinibi E, Retter A, Orczyk C, et al. Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. Eur Radiol. 2021;31(3):1644\u201355. Epub 2020\/10\/02. https:\/\/doi.org\/10.1007\/s00330-020-07256-z. PubMed PMID: 33000302; PubMed Central PMCID: PMCPMC7880925.","journal-title":"Eur Radiol"},{"issue":"11","key":"5702_CR33","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s00261-017-1169-5","volume":"42","author":"EJ Jordan","year":"2017","unstructured":"Jordan EJ, Fiske C, Zagoria RJ, Westphalen AC. Evaluating the performance of PI-RADS v2 in the non-academic setting. Abdom Radiol (NY). 2017;42(11):2725\u201331. Epub 2017\/04\/30. https:\/\/doi.org\/10.1007\/s00261-017-1169-5. PubMed PMID: 28451763.","journal-title":"Abdom Radiol (NY)"},{"key":"5702_CR34","doi-asserted-by":"publisher","unstructured":"Sharifi SHH, Williams A, Ryan JT, Ajami T, Nativ OF, Han S, et al. Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial. BJU Int. 2026. Epub 2026\/05\/06. https:\/\/doi.org\/10.1111\/bju.70303. PubMed PMID: 42089595.","DOI":"10.1111\/bju.70303"},{"issue":"5","key":"5702_CR35","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1097\/JU.0000000000002885","volume":"208","author":"P Doan","year":"2022","unstructured":"Doan P, Scheltema MJ, Amin A, Shnier R, Geboers B, Gondoputro W, et al. Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial. J Urol. 2022;208(5):1028\u201336. Epub 2022\/08\/11. https:\/\/doi.org\/10.1097\/JU.0000000000002885. PubMed PMID: 35947521.","journal-title":"J Urol"},{"issue":"5","key":"5702_CR36","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1007\/s00330-020-07336-0","volume":"31","author":"I Caglic","year":"2021","unstructured":"Caglic I, Sushentsev N, Gnanapragasam VJ, Sala E, Shaida N, Koo BC, et al. MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol. 2021;31(5):2696\u2013705. Epub 2020\/11\/17. https:\/\/doi.org\/10.1007\/s00330-020-07336-0. PubMed PMID: 33196886; PubMed Central PMCID: PMCPMC8043947.","journal-title":"Eur Radiol"},{"key":"5702_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.urology.2023.07.019","volume":"180","author":"Y Bhanji","year":"2023","unstructured":"Bhanji Y, Mamawala M, de la Calle CM, Landis P, Epstein JI, Simopoulos DN, et al. Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) Magnetic Resonance Imaging Scoring to Predict Clinical Outcomes in Active Surveillance for Grade Group 1 Prostate Cancer. Urology. 2023;180:194\u20139. Epub 2023\/08\/04. https:\/\/doi.org\/10.1016\/j.urology.2023.07.019. PubMed PMID: 37536582.","journal-title":"Urology"},{"key":"5702_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10795-4","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ, Thijssen LCP, Asbach P, Barrett T, et al. PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol. 2024;34(11):7068\u201379. Epub 2024\/05\/24. https:\/\/doi.org\/10.1007\/s00330-024-10795-4. PubMed PMID: 38787428; PubMed Central PMCID: PMCPMC11519155."},{"issue":"1133","key":"5702_CR39","doi-asserted-by":"publisher","first-page":"20211372","DOI":"10.1259\/bjr.20211372","volume":"95","author":"E Karanasios","year":"2022","unstructured":"Karanasios E, Caglic I, Zawaideh JP, Barrett T. Prostate MRI quality: clinical impact of the PI-QUAL score in prostate cancer diagnostic work-up. Br J Radiol. 2022;95(1133):20211372. Epub 2022\/02\/19. https:\/\/doi.org\/10.1259\/bjr.20211372. PubMed PMID: 35179971; PubMed Central PMCID: PMCPMC10993954.","journal-title":"Br J Radiol"},{"key":"5702_CR40","doi-asserted-by":"publisher","first-page":"110578","DOI":"10.1016\/j.mri.2025.110578","volume":"127","author":"KS Zhang","year":"2026","unstructured":"Zhang KS, Glemser PA, Neelsen CJO, Wennmann M, Rotkopf LT, Netzer N, et al. Repeatability and reproducibility of maximum diameter measurements of prostate lesions on MRI with repositioning and variation of imaging sequences: A test-retest study. Magn Reson Imaging. 2026;127:110578. Epub 2025\/11\/30. https:\/\/doi.org\/10.1016\/j.mri.2025.110578. PubMed PMID: 41317885.","journal-title":"Magn Reson Imaging"},{"issue":"1","key":"5702_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00330-022-09032-7","volume":"33","author":"C Roest","year":"2023","unstructured":"Roest C, Kwee TC, Saha A, Futterer JJ, Yakar D, Huisman H. AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study. Eur Radiol. 2023;33(1):89\u201396. Epub 2022\/08\/13. https:\/\/doi.org\/10.1007\/s00330-022-09032-7. PubMed PMID: 35960339; PubMed Central PMCID: PMCPMC9755080.","journal-title":"Eur Radiol"},{"key":"5702_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-026-01107-6","author":"J Liu","year":"2026","unstructured":"Liu J, Woon DTS, Ahmad W, Cundy TP, Chengodu T, Desai N, et al. Exploring the utility of artificial intelligence in identifying progression of prostate cancer during active surveillance: A systematic review. Prostate Cancer Prostatic Dis. 2026. Epub 2026\/05\/13. https:\/\/doi.org\/10.1038\/s41391-026-01107-6. PubMed PMID: 42120496.","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05702-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05702-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05702-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:48:08Z","timestamp":1785559688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05702-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":42,"alternative-id":["5702"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05702-y","relation":{"references":[{"id-type":"doi","id":"10.1007\/s00330-024-10795-4","asserted-by":"subject"}]},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}